Given mounting evidence of the efficacy of glucagon-like peptide-1 receptor agonists and sodium glucose co-transporter-2 inhibitors for improving cardiovascular outcomes in patients with diabetes independent of effects on glycemia [35–40], optimal cardiovascular disease prevention through diabetes treatment may depend on both individualized glycemic control goals and medication choice. The gene discussed is GLP1R; the disease is diabetes mellitus.